T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification.
暂无分享,去创建一个
Martin Friedlander | Edith Aguilar | Michael I Dorrell | E. Aguilar | M. Friedlander | E. Banin | Matthew R Ritter | C. Aderman | M. R. Ritter | Alexandra C. H. Smith | J. Friedlander | Michael I. Dorrell | Eyal Banin | Christopher M Aderman | Alexandra C H Smith | Jeffrey Friedlander
[1] Y. Ogura,et al. Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease , 2003, Nature Medicine.
[2] A. Madan,et al. Animal models of oxygen-induced retinopathy. , 2003, Frontiers in bioscience : a journal and virtual library.
[3] D. S. Mcleod,et al. Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy. , 2002, Investigative ophthalmology & visual science.
[4] Alan W. Stitt,et al. Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. , 2005, The American journal of pathology.
[5] S. Shih,et al. Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[6] J. Reader,et al. Biologically active fragment of a human tRNA synthetase inhibits fluid shear stress-activated responses of endothelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[7] Joan W. Miller,et al. VEGF164-mediated Inflammation Is Required for Pathological, but Not Physiological, Ischemia-induced Retinal Neovascularization , 2003, The Journal of experimental medicine.
[8] N. Ashton. Oxygen and the growth and development of retinal vessels. In vivo and in vitro studies. The XX Francis I. Proctor Lecture. , 1966, American journal of ophthalmology.
[9] Lois E. H. Smith,et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. , 1997, Science.
[10] Martin Friedlander,et al. Retinal vascular development is mediated by endothelial filopodia, a preexisting astrocytic template and specific R-cadherin adhesion. , 2002, Investigative ophthalmology & visual science.
[11] P. Schimmel,et al. A human aminoacyl-tRNA synthetase as a regulator of angiogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[12] L. Cornelius,et al. Matrix metalloproteinases: pro- and anti-angiogenic activities. , 2000, The journal of investigative dermatology. Symposium proceedings.
[13] R. Visse,et al. This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .
[14] Marcus Fruttiger,et al. Development of the mouse retinal vasculature: angiogenesis versus vasculogenesis. , 2002, Investigative ophthalmology & visual science.
[15] Jane Sottile,et al. Regulation of angiogenesis by extracellular matrix. , 2004, Biochimica et biophysica acta.
[16] V. Rajaratnam,et al. Variable oxygen and retinal VEGF levels: correlation with incidence and severity of pathology in a rat model of oxygen-induced retinopathy. , 2004, Experimental eye research.
[17] J. Rakic,et al. Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials. , 2003, Investigative ophthalmology & visual science.
[18] P. Schimmel,et al. A fragment of human TrpRS as a potent antagonist of ocular angiogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[19] Lawrence A. Yannuzzi,et al. PRECLINICAL AND PHASE 1A CLINICAL EVALUATION OF AN ANTI-VEGF PEGYLATED APTAMER (EYE001) FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION , 2002, Retina.
[20] E. Duh,et al. Stimulation of neovascularization by the anti-angiogenic factor PEDF. , 2004, Investigative ophthalmology & visual science.
[21] G. Gasparini,et al. Anti-angiogenic therapy: Rationale, challenges and clinical studies , 2004, Angiogenesis.
[22] L. Aiello,et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[23] Yihai Cao. Antiangiogenic cancer therapy. , 2004, Seminars in cancer biology.
[24] J. Reader,et al. VE-cadherin Links tRNA Synthetase Cytokine to Anti-angiogenic Function* , 2005, Journal of Biological Chemistry.
[25] Lois E. H. Smith,et al. Oxygen-induced retinopathy in the mouse. , 1994, Investigative ophthalmology & visual science.
[26] Lois E. H. Smith,et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[27] W. Stetler-Stevenson,et al. Proteases in invasion: matrix metalloproteinases. , 2001, Seminars in cancer biology.
[28] Q. Sang,et al. Complex role of matrix metalloproteinases in angiogenesis , 1998, Cell Research.
[29] P. Campochiaro,et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. , 2000, The American journal of pathology.
[30] J. Folkman,et al. Blood Vessel Formation: What Is Its Molecular Basis? , 1996, Cell.
[31] D. Yew,et al. Time-course expression of vascular endothelial growth factor as related to the development of the retinochoroidal vasculature in rats , 1998, Experimental Brain Research.
[32] L. Devy,et al. The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[33] J. Carter,et al. Purification of a highly modified RNA-aptamer. Effect of complete denaturation during chromatography on product recovery and specific activity. , 1999, Journal of chromatography. B, Biomedical sciences and applications.
[34] A. Otani,et al. Retinal Vascular Regeneration , 2005, Seminars in ophthalmology.
[35] J. Reader,et al. Erratum: VE-cadherin links tRNA synthetase cytokine to antiangiogenic function (Journal of Biological Chemistry (2005) 280 (2405-2408)) , 2007 .
[36] Crystal Structure of Human Tryptophanyl-tRNA Synthetase Catalytic Fragment , 2004, Journal of Biological Chemistry.
[37] Leh Smith. Pathogenesis of retinopathy of prematurity , 2002, Acta paediatrica (Oslo, Norway : 1992). Supplement.
[38] E. Piek,et al. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. , 2003, Developmental biology.
[39] E. Gragoudas,et al. Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.
[40] Lois E. H. Smith,et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor , 1999, Nature Medicine.
[41] P. Schimmel,et al. Bone marrow–derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis , 2002, Nature Medicine.